All In Biotech

Drug Trial Radar · NCT05900141

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

41

Actual

Start

Sep 29, 2023

Primary completion

Oct 15, 2026

Study completion Oct 15, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This non-randomized, open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants in Germany with hyperlipoproteinemia(a) and established cardiovascular disease who have successfully completed the double-blind parent study (CTQJ230A12302). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint.

Conditions

  • Hyperlipoproteinemia (a)

Interventions

  • PelacarsenDrug

    Pelacarsen 80mg s.c. monthly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse events (AEs) or serious adverse events (SAEs), including changes in laboratory evaluations, vital signs qualifying and reported as AEs.Time frame: 60 months
  2. Duration of drug exposureTime frame: 60 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Cloppenburg, Germany

  • Novartis Investigative Site

    Erlangen, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Munich, Bavaria, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.